Case-Based Learning: Unexplained Steatorrhea With Normal Pancreatic Testing

Abstract

Steatorrhea, characterized by excessive fat excretion in stools, is a common clinical presentation that often prompts evaluation of pancreatic exocrine function. However, when pancreatic testing is normal, the differential diagnosis becomes complex and necessitates a broader, mechanism-based approach. This article reviews the current understanding of unexplained steatorrhea with normal pancreatic testing, focusing on epidemiology, underlying pathophysiology, risk factors, clinical features, diagnostic strategies, management, recent advances, and evidence-based recommendations for clinicians. Emphasis is placed on integrating guideline-directed care with emerging diagnostic and therapeutic innovations, providing a comprehensive resource for healthcare professionals managing this challenging clinical scenario.

Introduction

Steatorrhea, defined as the passage of bulky, pale, foul-smelling stools with increased fat content, is frequently associated with malabsorptive disorders. The initial workup typically includes assessment of pancreatic exocrine function, as pancreatic insufficiency is a leading cause. However, a subset of patients present with persistent steatorrhea despite normal pancreatic enzyme output and structure on imaging and function tests. This scenario poses a diagnostic and therapeutic challenge for clinicians, necessitating consideration of alternative etiologies and a systematic, evidence-based approach. Understanding the broad spectrum of causes, clinical manifestations, and management options is essential for optimizing patient outcomes in cases of unexplained steatorrhea with normal pancreatic testing.

Epidemiology / Disease Burden

The precise epidemiology of unexplained steatorrhea is not well delineated, largely due to underrecognition and the heterogeneous nature of underlying etiologies. Steatorrhea itself is a symptom rather than a disease, occurring in diverse conditions such as celiac disease, small intestinal bacterial overgrowth (SIBO), bile acid malabsorption, and rare congenital disorders. Studies estimate that non-pancreatic causes account for approximately 20-30% of steatorrhea cases in tertiary gastroenterology settings. The disease burden is significant, with patients experiencing impaired quality of life, nutritional deficiencies, and increased risk of complications such as osteoporosis and cardiovascular disease.

Pathophysiology

In the context of normal pancreatic function, steatorrhea results from disruptions in the digestion, emulsification, or absorption of dietary fat. Mechanisms include impaired bile acid synthesis or secretion (as seen in cholestatic liver disease), defective micelle formation (due to bile acid malabsorption), or mucosal abnormalities (such as villous atrophy in celiac disease). Additionally, disorders affecting enterocyte function (e.g., abetalipoproteinemia, microvillus inclusion disease) or lymphatic transport (intestinal lymphangiectasia) can lead to fat malabsorption. SIBO can also disrupt fat absorption by deconjugating bile acids and damaging the mucosa. Identifying the precise pathophysiological mechanism is critical for targeted management.

Risk Factors

Risk factors for non-pancreatic steatorrhea include a history of gastrointestinal surgery (especially ileal resection), chronic liver disease, autoimmune conditions, family history of malabsorptive disorders, and use of medications that interfere with bile acid metabolism (e.g., cholestyramine, certain antibiotics). Genetic predisposition plays a role in conditions such as celiac disease and congenital transport defects. Other contributing factors include advanced age, altered gut motility, and immune compromise, which can predispose to SIBO and mucosal injury.

Clinical Features

Patients typically present with chronic diarrhea, greasy stools, weight loss, bloating, and signs of fat-soluble vitamin deficiencies (A, D, E, K). Clinical clues suggesting non-pancreatic causes include a history of gluten sensitivity, concomitant liver dysfunction, or symptoms related to small bowel disease. Extraintestinal manifestations such as dermatitis herpetiformis (in celiac disease), peripheral edema (in protein-losing enteropathy), and neurologic symptoms (due to vitamin deficiencies) may provide diagnostic direction. Physical examination may reveal signs of malnutrition, muscle wasting, glossitis, and peripheral neuropathy.

Diagnosis

Diagnosis requires a stepwise approach, beginning with clinical suspicion and confirmation of steatorrhea, typically through quantitative fecal fat analysis. Once pancreatic pathology is excluded via normal fecal elastase, serum trypsinogen, and imaging, further evaluation should focus on small bowel and hepatobiliary causes. Serologic testing for celiac disease (anti-tTG and EMA antibodies), hydrogen breath testing for SIBO, assessment of bile acid malabsorption (SeHCAT scan or serum 7αC4), and stool studies for parasitic infections are recommended. In selected cases, endoscopy with small bowel biopsy and capsule endoscopy may be warranted. Advanced genetic testing may be necessary for suspected congenital disorders.

Treatment & Management

Management is etiology-specific. In celiac disease, strict gluten-free diet leads to resolution of steatorrhea and mucosal healing. SIBO is managed with antibiotics (e.g., rifaximin), dietary modification, and addressing underlying motility disorders. Bile acid malabsorption responds to bile acid sequestrants such as cholestyramine, while congenital transport defects may require specialized nutritional support including medium-chain triglycerides and fat-soluble vitamin supplementation. General measures include correction of nutritional deficiencies, pancreatic enzyme supplementation only if pancreatic reserve is borderline, and regular monitoring for metabolic bone disease and cardiovascular risk.

Recent Advances / Emerging Therapies

Recent advances include noninvasive diagnostic biomarkers such as serum 7αC4 for bile acid diarrhea and the use of next-generation sequencing for rare genetic conditions. Fecal microbiota transplantation is under investigation for refractory SIBO and other dysbiosis-related malabsorption. Novel therapies targeting bile acid pathways, such as ileal bile acid transporter inhibitors, are being explored for bile acid diarrhea. Advances in endoscopic techniques, including balloon-assisted enteroscopy, have improved diagnostic yield in obscure small bowel disorders. Ongoing research aims to clarify the role of the microbiome and personalized nutrition in managing unexplained steatorrhea.

Guideline Recommendations

Current guidelines from gastroenterological societies emphasize the exclusion of pancreatic insufficiency as a first step, followed by a tailored workup based on clinical context. Screening for celiac disease is recommended in all patients with unexplained steatorrhea. Breath testing for SIBO and assessment for bile acid diarrhea are advised when clinical suspicion is high. Nutritional assessment, including fat-soluble vitamin levels and bone density, should be performed routinely. Multidisciplinary care involving gastroenterologists, dietitians, and genetic counselors is advocated for complex cases.

Conclusion

Unexplained steatorrhea with normal pancreatic testing represents a diagnostic and management challenge that requires a systematic, evidence-based approach. Recognition of alternative etiologies, understanding of underlying mechanisms, and application of recent diagnostic and therapeutic advances are essential for optimal patient care. Guideline-directed evaluation and individualized management can significantly improve outcomes, reduce complications, and enhance quality of life for affected patients. Ongoing research and multidisciplinary collaboration remain critical to advancing care in this complex clinical scenario.